| Date |
Event |
Presentation |
Speakers |
|
December 2, 2015
|
PERSONALISED MEDICINES & BIOMARKERS 2015
|
Panelists
|
Chris Harbron, Darren Hodgson
|
|
April 6, 2013
|
AACR Annual Meetings
|
Drug Development Track: New Drugs on the Horizon 1 Co-Chairpersons: Lori S. Friedman, Genentech, Inc., South San Francisco, CA, and Simon Bailey, Pfizer, Inc., San Diego, CA
|
Dennis Huszar
|
|
September 13, 2012
|
International Society of Gastrointestinal Oncology
|
Summary
|
David Wilson
|
|
May 23, 2012
|
Biomarkers World Europe 2012
|
qEEG and ERP as translational biomarkers in drug development for the symptomatic treatment of Alzheimer’s Disease
|
Märta Segerdahl
|
|
November 15, 2011
|
Cosa 38th Annual Scientific Meeting
|
The role of the pathologist in drug research and development
|
Chris Womack
|
|
February 24, 2011
|
Targeting P13K / mTOR Signaling in Cancer
|
Pharmacology of AZD8055, a selective mTOR kinase inhibitor
|
Sylvie M. Guichard
|
|
January 31, 2011
|
Biomarkers Summit
|
STREAM ONE | PRECLINICAL CANCER MODELS USED IN DRUG DISCOVERY AND TRANSLATIONAL ONCOLOGY
|
Robert Wilkinson
|
|
|
|
THE APPLICATION OF INFORMATICS TO BIOMARKER DEVELOPMENT
|
Hugh Salter
|
|
|
|
ISSUES IN STATISTICAL VALIDATION OF BIOMARKERS AS SURROGATE ENDPOINTS IN CLINICAL TRIALS
|
Ziad Taib
|
|
August 23, 2010
|
The Ubiquitin Drug Discovery & Diagnostics Conference
|
Ubiquitin Specific Proteases as novel drug targets – A case study
|
Jonathan D. Wrigley
|
|
May 4, 2010
|
Biomarker World Congress 2010
|
New Era with Targeted Drugs: New Development Approaches are Needed to Achieve Success
|
Geert J.C.M. Kolvenbag
|
|
April 30, 2010
|
Drug Story
|
Development of a Portfolio of Therapeutic Antibodies for Oncology Combining Xenomouse and Display Technologies
|
David Blakey
|
|
April 6, 2010
|
IBCs 5th Annual China 2010 Pharmaceutical R&D Summit
|
4 Case Study: Conducting Proof-of-Concept Studies in China
|
Karen Atkin
|
|
February 24, 2010
|
5th Annual Bioanalysis in Clinical Research
|
An approach to the validation of flow cytometry methods in the regulatory environment
|
Ruth Coldwell
|
|
|
|
Validation and subsequent application of an immunoassay method for the determination of GRO-alpha in human serum
|
Karen Elsby
|
|
September 23, 2009
|
Track 2: Implementing Personalized Medicine : Inaugural Personalized Medicine
|
Delivering on the Promise of Personalized Healthcare: Examples from AstraZeneca
|
Ruth E. March
|
|
September 23, 2009
|
TRACK 4: Bridging Silos in Biomarker Development : Third Annual Biomarker Data Analysis
|
New Biomarkers: Opportunities and Challenges
|
Anastasia M. Khoury Christianson
|
|
August 5, 2009
|
Targets in Context - Linking Targets to Diseases Agenda
|
Comparison of Whole-Cell, Label-Free Assays for GPCR Drug Discovery
|
Matthew Peters
|
|
August 5, 2009
|
Drug Safety Strategies to De-Risk Compounds
|
Developing Computational Biology in Toxicology: Predictions, Data and Culture
|
Sherri Matis-Mitchell
|
|
|
|
How Can Systems Biology Help in De-risking Molecules?
|
David Cook
|
|
June 16, 2009
|
4th Annual Cell Based Assays
|
Modelling Tumour Microenvironment by High-Content Analysis of Complex Cell Models
|
Beverley Isherwood
|
|
|
|
Cell assay strategies for nuclear hormone receptors - the evolution of assay formats to improve quality and throughput
|
Graeme Walker
|
|
|
|
Profiling drug mode of action through high content assays; application of multiparametric data analysis and statistical tools
|
Peter Caie
|
|
June 9, 2009
|
Cell and Tissue-Based Assays for HTS
|
Screening Bone Marrow Toxicity Using a Tiered Approach
|
David Brott
|
|
June 4, 2009
|
Structure-Based Drug Design
|
Supplementing Structural Information with Biophysical Data: Adding Value and Understanding in Lead Generation
|
Stefan Geschwindner
|
|
|
|
Designing Drugs against Multiple Parameters: Scoring Functions for Multi-Parameter Ligand Based De Novo Design
|
James R. Damewood
|
|
April 7, 2009
|
Kinase Inhibitor Chemistry - Charting the Chemical Space
|
Identification of Potent and Selective Inhibitors of Trk Kinases
|
Tao Wang
|
|
January 27, 2009
|
6th Annual Clinical Trial Performance Metrics
|
Maximising the return on investment of clinical trials metrics – using metrics to implement process improvement to improve delivery and productivity in Clinical Trials
|
Diane Dootson
|
|
|
|
Keynote: How AstraZeneca is approaching metrics concerning patient recruitment
|
Niclas Pantzar
|
|
|
|
Investigator metrics – how metrics can help to improve investigator performance
|
Ramil Abdrachitov
|
|
December 4, 2008
|
BIT Life Sciences 2nd Annual World Congress of Gene-2008 (WCG 2008)
|
Session Chair :Track 1-10
|
James Jianguo Li
|
|
|
|
Small Molecule Inhibitors Targeting Mutation Driven Cancers :Track 2-4 (I)
|
Jeannie Hou
|
|
December 2, 2008
|
4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development
|
1: Modelling with 3D high-content cellular imaging in drug discovery
|
Neil Carragher,
|
|
|
|
2 : How does imaging help? A thorough analysis of translating preclinical to clinical trials using imaging methods
|
Harsukh , Parmar
|
|
|
|
2 : Successful implementation of fMRI (functional MRI) and phMRI (pharmacological MRI) in preclinical analgesia studies
|
Jeremy Young,
|
|
|
|
2 : Panel Debate: How translatable is preclinical and clinical imaging?
|
Harsukh , Parmar
|
|
November 26, 2008
|
Speed and Safety in Drug Discovery
|
Humanising drug discovery to make earlier & better Stop/Go decisions in Pharma R&D
|
Paul Newbold
|
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
Fingerprint Based Methods for Predicting Sites of Metabolism
|
C Scott Boyer
|
|
|
|
Relevance of In Vitro and In Vivo Models to Cardiovascular Toxicity
|
Tim Hammond
|
|
April 30, 2008
|
Protein Scale-Up & Manufacturing
|
Registration Open
|
Stefan R. Schmidt
|
|
April 28, 2008
|
Clinical Development of Therapeutic Antibodies
|
Development of a New Fully Human Anti-CD20
|
Gadi Bornstein
|
|
|
|
Preclinical and Clinical Safety of Monoclonal Antibodies
|
Richard Knight
|
|
April 27, 2008
|
Phage Display of Antibodies and Peptides
|
Development of a Portfolio of Therapeutic
|
David Blakey
|
|
March 25, 2008
|
R&D Risk Mitigation
|
Negotiating the Partnership
|
William F Mongan
|
|
March 25, 2008
|
Clinical Trials Asia
|
Utilizing and Integrating Global Clinical Study Local Data from China to Mutually Support Global and Local Applications in Order to Benefi t Unmet Medical Needs
|
James Cai
|
|
February 3, 2008
|
AACR - Cytoskeletal Signaling in Cancer
|
SESSION 7: CYTOSKELETON COMPONENTS AS CANCER TARGETS
|
Nicholas J. Keen
|
|
December 4, 2007
|
7th World Drug Discovery & Development Summit 2007
|
BIOMARKERS AND PERSONALISED MEDICINE OF THE FUTURE
|
Prof. Ian Wilson
|
|
November 29, 2007
|
Fourth Annual In Vivo Molecular Imaging: Bridging the Gap from Discovery to Clinical Applications Nov (29-30)
|
Clinical Applications (13:40-17:30)
|
Chi-Ming Lee
|
|
|
|
Clinical Applications: PET as a Translational Tool for CNS Drug Development (15:20-15:50)
|
Chi-Ming Lee
|
|
November 7, 2007
|
Srial II: Advances and Challenges Toward Major Diseases: Extension on New Hope Nov (07-13)
|
Session 15: Anti-Cancer/Tumors Drug Discovery & Development and Current Status of the Innovative Therapeutics (Part III) (13:30-17:00)
|
Xiaolin Zhang
|
|
|
|
Session 15: AZD1152, an Aurora B Kinase Inhibitor, Demonstrates Potent Antitumour Efficacy in Preclinical Models (16:15-16:40)
|
Xiaolin Zhang
|
|
November 5, 2007
|
Second Annual Biomarkers Europe Nov (05-06)
|
BIOMARKERS IN PERSONALIZED MEDICINE: Quantifying the Additional Benefits of Proteomics in Patient Selection (16:00-16:30)
|
Chris Harbron
|
|
|
|
BIOMARKERS IN PERSONALIZED MEDICINE: Genome-Wide Pharmacogenetic Investigation of Adverse Events: A Case Study (13:15-13:45)
|
Ruth E. March
|
|
|
|
BIOMARKERS IN PERSONALIZED MEDICINE (13:10-17:00)
|
Ruth E. March, Chris Harbron
|
|
|
|
BIOMARKERS FOR SAFETY ASSESSMENT (14:00-15:45)
|
Graham Betton
|
|
|
|
BIOMARKERS FOR SAFETY ASSESSMENT: Biomarkers of Nephrotoxicity in Toxicology and the Clinic (14:00-14:30)
|
Graham Betton
|
|
October 17, 2007
|
Exploring Next Generation Sequencing: Applications and Case Studies (Oct 17-18)
|
Deep Sequencing: Sensitive Detection of Somatic Mutations Using Deep Sequencing and ARMS Allele Specific PCR (14:35-15:05)
|
Neil Gibson
|
|
|
|
Deep Sequencing (12:00-15:30)
|
Neil Gibson
|
|
October 16, 2007
|
Inaugural Kinbase Inhibitors: Moving Forward into Clinical Studies Oct (16-17)
|
Clinical Trials (12:10-19:30)
|
Robert Wilkinson
|
|
|
|
Clinical Trials: AZD1152, a Highly Potent and Selective Inhibitor of Aurora B Kinase (14:55-15:25)
|
Robert Wilkinson
|
|
October 15, 2007
|
Cambridge Healthtech Institute's Third Annual Mastering Process Chemistry Oct (15-17)
|
PROCESS OPTIMIZATION VIA ANALYTICS: Anticipation of Scale-Up Issues in Process Development: Scale Up Risk Evaluation (SURE) (16:35-17:05)
|
Frans L. Muller
|
|
|
|
PROCESS OPTIMIZATION VIA ANALYTICS (14:00-15:05)
|
Frans L. Muller
|
|
September 30, 2007
|
Bridging Pharma and IT - Leveraging Information Technology to Improve Productivity (Sep30-Oct2)
|
BRIDGING CLINICAL AND IT: Integrated Biomedical Image Data Management and Analytics (11:00-11:45)
|
Goutham Edula
|
|
|
|
BRIDGING CLINICAL AND IT (09:30-15:30)
|
Goutham Edula
|
|
September 27, 2007
|
Protein Expression Europe (Sep 27-28)
|
Protein Localization (13:25-16:15)
|
Stefan R. Schmidt
|
|
|
|
Protein Localization: Comments by Session Chairperson (13:25-13:30)
|
Stefan R. Schmidt
|
|
|
|
Breakfast BuzZ Sessions (08:00-09:00)
|
Niek Dekker
|
|
|
|
Breakfast BuzZ Session IV: Sampling Expression Space (08:00-09:00)
|
Niek Dekker
|
|
|
|
Drug Discovery Applications (13:00-15:15)
|
Niek Dekker
|
|
|
|
Drug Discovery Applications: Purified Membrane Protein Targets for Drug Discovery (13:45-14:15)
|
Niek Dekker
|
|
September 17, 2007
|
Biomarker Discovery Summit: Bridging the Silos in Biomarker Discovery & Validation (Sep17-19)
|
Third annual Genomic Biomarkers: PHARMACOGENETICS: Major Pharmacogenetics Studies Using a Combination of Genome-Wide Tagging SNPs and High Density SNP Genotyping in Candidate Genes (10:05-10:35)
|
Neil Gibson
|
|
|
|
Third annual Genomic Biomarkers: PHARMACOGENETICS (08:30-11:30)
|
Neil Gibson
|
|
|
|
Eight Annual Metabolic Biomarkers: METABOLIC BIOMARKER DISCOVERY (08:30-11:00)
|
Stephen Furlong
|
|
|
|
Eight Annual Metabolic Biomarkers; METABOLIC BIOMARKER DISCOVERY: Urine and Plasma Biomarkers in Schizophrenia (09:05-09:35)
|
Stephen Furlong
|
|
July 14, 2007
|
BIOLOGY OF CALPAINS IN HEALTH AND DISEASE
|
Oncogene mediated calpain activation
|
Neil Carragher
|
How We Rank